Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Recognitions, Shareholder Meeting Schedules, Partnerships, and Technical Updates - Analyst Notes on WellPoint, Medtronic, Auxilium, Sirona and ImmunoGen

NEW YORK, June 17, 2014 /PRNewswire/ --



Today, Analysts Review released its analysts' notes regarding WellPoint Inc. (NYSE: WLP), Medtronic, Inc. (NYSE: MDT), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Sirona Dental Systems Inc. (NASDAQ: SIRO) and ImmunoGen Inc. (NASDAQ: IMGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3788-100free.

--
WellPoint Inc. Analyst Notes
On June 11, 2014, WellPoint Inc. (WellPoint) reported that American Heart Association has recognized the Company as a Platinum-Level Fit-Friendly Worksite for helping employees eat better and move more. Commenting on the recognition, WellPoint Director of Wellness Programs, Pamela Ventura, stated, "Our programs target key health improvement opportunities - move more, stress less, eat better, practice prevention and stop smoking. We're committed to providing the best workplace environment possible and being recognized by the American Heart Association as a Platinum-Level Fit-Friendly Worksite reinforces the work we've done so far." The Company stated that the Fit-Friendly Worksites program serves as positive motivation for the American workforce by helping worksites prioritize their employees' health and wellness. The full analyst notes on WellPoint are available to download free of charge at:

http://www.analystsreview.com/Jun-17-2014/WLP/report.pdf

--
Medtronic, Inc. Analyst Notes
On June 11, 2014, the Board of Directors of Medtronic, Inc. (Medtronic) announced that the Company's Annual Meeting of Shareholders will be held on August 21, 2014, at 10:30 a.m. CDT. According to the Company, the meeting will take place at Medtronic's Mounds View campus, located at 8200 Coral Sea Street N.E., Mounds View, Minnesota. Additionally, the Company stated that shareholders of record as of the close of business on June 23, 2014 will be eligible to vote at the meeting. The full analyst notes on Medtronic are available to download free of charge at:

http://www.analystsreview.com/Jun-17-2014/MDT/report.pdf

--
Auxilium Pharmaceuticals Inc. Analyst Notes
On June 11, 2014, Auxilium Pharmaceuticals Inc. (Auxilium) announced that the Company has partnered with Prasco, LLC (Prasco) to introduce an Authorized Generic version of Testim® (testosterone gel). According to the Company, Testim along with its Authorized Generic version are U.S. Food and Drug Administration (FDA) approved testosterone gels to treat adult males with low or no testosterone. Prasco has product inventory available and has commenced shipping product, and Auxilium will maintain responsibility for the manufacture of Testim and the Authorized Generic testosterone gel, as well as for the distribution of branded Testim. Commenting on the launch, Company CEO and President Adrian Adams, stated, "We believe the launch of this Authorized Generic of Testim with Prasco could expand the Testim franchise market, build upon our efforts to manage Testim as a mature brand and enable Auxilium to realize maximum shareholder value." The full analyst notes on Auxilium are available to download free of charge at:

http://www.analystsreview.com/Jun-17-2014/AUXL/report.pdf

--
Sirona Dental Systems Inc. Analyst Notes
On June 12, 2014, Sirona Dental Systems Inc.'s (Sirona) stock slipped by 0.05%, closing at $77.20. Over the past five day trading period, Company stock went up by 0.59% compared to the Nasdaq Composite which increased by 0.03% during the same trading session. The full analyst notes on Sirona are available to download free of charge at:

http://www.analystsreview.com/Jun-17-2014/SIRO/report.pdf

--
ImmunoGen Inc. Analyst Notes
On June 12, 2014, ImmunoGen Inc.'s (ImmunoGen) stock increased by 8.82%, ending the day at $13.20. On the same day, The Street reported that the Company was upgraded by UBS to "neutral" from "sell" with a price target of $13. Company stock went up by 8.73% over the previous three day trading session, compared to the Nasdaq Composite which decreased by 0.89% during the same trading session. The full analyst notes on ImmunoGen are available to download free of charge at:

http://www.analystsreview.com/Jun-17-2014/IMGN/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com .

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com .

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Analysts Review

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.